Genitourinary Cancer News

The FDA granted accelerated approval to the combination of enfortumab vedotin-ejfv and pembrolizumab as first-line treatment for cisplatin-ineligible adults with locally advanced or metastatic urothelial carcinoma.

HHS on Monday released the National Cancer Plan, which includes eight goals and strategies to prevent cancer, reduce related mortality and improve the lives of people living with the disease.

FDA granted full approval to pembrolizumab for treatment of certain adults and children with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors as determined through an FDA-approved test.

Community oncologists who received peer coaching from cancer genetics experts more frequently ordered genetic testing for their patients, according to study results.

A combination of lenvatinib and pembrolizumab continued to provide a greater survival benefit than sunitinib among patients with advanced renal cell carcinoma, an updated analysis of the randomized phase 3 CLEAR study showed.

Researchers at Cancer Care Alberta and University of Calgary have demonstrated the value of a cancer symptom algorithm in correctly identifying which patients may be at high risk for an unplanned ED visit.

Aggressive end-of-life care remains common among older individuals with metastatic cancer despite increased efforts over the past several decades to reduce such interventions, according to study results published in JAMA Network Open.

SAN FRANCISCO — Healio spoke with Moshe Ornstein, MD, about the COSMIC-313 trial presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Moshe Ornstein, MD, highlights findings from the follow-up data of the CheckMate 9ER trial presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Moshe Ornstein, MD, discusses interim results from the CaboPoint study presented at the annual ASCO Genitourinary Cancers Symposium.